Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with and submissions to regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to address questions raised by regulatory agencies and to receive approval for phase 2 trial design, the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that the phase 2 trial for AT2220 is not resumed in a timely manner, or at all, and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials may not be predictive of future results. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securiti
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... COLORADO SPRINGS, Colo. , Aug. 22, 2014 ... Company specializing in cannabis formulation-based drug development and ... of UFCM iCare,s third international medical cannabis conference ... Strasbourg, France , on October ... experts with other stakeholders, such as researchers, health ...
(Date:8/21/2014)... Aug. 21, 2014  Aptuit LLC announces that ... Indiana , has enhanced its capabilities in ... small and large molecules, including biologic drugs, metabolites, ... maXisPlus Q-TOF mass spectrometer. In making ... Aptuit, said, "The expanded large molecule capability enhances ...
(Date:8/21/2014)...  eRelevance Corporation ( www.erelevancecorp.com ), a progressive ... has completed integration with Nextech, a popular Electronic ... Dermatology practices. "Integration allows our service ... using Nextech," stated Bob Fabbio , co-founder ... the EMR we are able to automatically target ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... March 29, 2011 Boston Scientific Corporation (NYSE: ... and events schedule at the 60th Annual Scientific Session ... 2011 in New Orleans. "Twelve-month results from ... on our next-generation PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) ...
... Calif., March 29, 2011 CryoLife, Inc. (NYSE: ... cardiovascular tissue processing company, and Cardiogenesis Corporation (OTCQB: CGCP), ... treatment of patients with refractory angina resulting from diffuse ... directors of both companies have approved a definitive agreement ...
Cached Medicine Technology:Boston Scientific Announces Its ACC 2011 Schedule 2Boston Scientific Announces Its ACC 2011 Schedule 3Boston Scientific Announces Its ACC 2011 Schedule 4Boston Scientific Announces Its ACC 2011 Schedule 5Boston Scientific Announces Its ACC 2011 Schedule 6CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 2CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 3CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 4CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 5CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 6CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 7CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 8CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 9CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 10CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 11CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 12CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 13CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 14CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 15CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 16CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 17CryoLife Signs Definitive Agreement to Acquire Cardiogenesis 18
(Date:8/22/2014)... Los Angeles, CA (PRWEB) August 22, 2014 ... post-production. Luciana Lagana , aka Dr. Luciana, is finding ... a limited budget and while taking care of hundreds of ... The 10-minute trailer for the show is completed, and she ... with other fun projects including those of her husband, actor/screenwriter ...
(Date:8/22/2014)... August 22, 2014 Until now, those with ... crutches or walkers to keep mobile. Thanks to an inventor ... much more effective. , He developed a prototype for the ... injured leg or foot but provide comfort and reduce pain ... different heights, it is also convenient and easy to install ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Braverman Eye ... in Fort Lauderdale at the most affordable fee. They ... eyesight through their advanced Lasik treatments. LASIK is a ... the Braverman Eye Center has been delivering successful LASIK ... live a glasses-free and contact lenses-free life with the ...
(Date:8/22/2014)... breathing difficulties, fainting. Each year approx. 265,000 Danes are ... illness. New research from Aarhus University and Aarhus University ... many as every fourth patient are sent home ... that led to the acute hospitalisation., "Naturally, there is ... the hospital disprove that there is a serious illness. ...
(Date:8/22/2014)... provides insight on how the brain processes external input ... and sides of the body, in order to select ... in the journal Neuron , show that the ... of sensory information, with specialised functional roles for the ... input structure in the basal ganglia, and is typically ...
Breaking Medicine News(10 mins):Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Many patients are discharged without a diagnosis 2Health News:The striatum acts as hub for multisensory integration 2
... have discovered a protein called TAT-5 that affects the ... from the surface of cells, capable of sending signals ... tumor spread, blood clotting and inflammation. Their discovery gives ... new potential strategies to manipulate diseases such as cancer. ...
... such in the workplace are more likely to have ... who do not, according to a new study from ... in the Workplace: How the Experiences of Transsexual Employees ... of the Journal of Vocational Behavior. ,For the ...
... The American Society for Gastrointestinal Endoscopy (ASGE) and the ... issued a new white paper on the potential role ... obesity-related diseases like Type 2 diabetes. The ... appears online in both GIE: Gastrointestinal Endoscopy, ...
... new national plan of action provides a roadmap for improving ... often unrecognized brain condition that affects approximately seven million hospitalized ... Bring an Ancient Disease into the 21st Century," written on ... to the Nov. 2011 issue of the Journal of ...
... GUELPH, ONTARIO -- Marketable yields of organic horticultural crops ... other factors restrict widespread adoption of organic production. Researchers ... grown in organic substrates amended with vermicompost and compared ... medium. "More research in this area is needed to ...
... is different than the metabolism of healthy people. And ... breath are different too. A new device pioneered at ... University in Haifa, Israel uses gold nanoparticles to trap ... these molecular signatures to control groups, the device can ...
Cached Medicine News:Health News:'Trans-parency' in the workplace 2Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 2Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 3Health News:Protecting our brains: Tackling delirium 2Health News:Protecting our brains: Tackling delirium 3Health News:New device uses gold nanoparticles to test for lung cancer 2Health News:New device uses gold nanoparticles to test for lung cancer 3
Nature's Remarkable Skin Protector -- Karaya 5 is a natural skin barrier that is particularly well suited for skin problems or for sensitive skin where reactions may have occurred to other types of s...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Security and confidence assured with porous tape, internal non-reflux valves, convenient drain valve....
Inquire...
Inquire...
Medicine Products: